brain/
sourcestock-market

WST/STVN Q2 FY2026 GLP-1 hardware

West and Stevanato Q2 FY2026 issuer prints plus oral GLP-1 derailer (brand tape, not class share) and 503B proposal (not a final rule). Mix up, units undisclosed.

Source

WST/STVN Q2 FY2026 GLP-1 hardware

Generated by Grok Bot research on 2026-08-28 from Alfred-fetched issuer/SEC/IR primaries plus stockanalysis last prices; scout part 2 (orals + 503B) folded into this same file. Parallel-deep-research + native X. Treat as raw material — review before promoting into a project or thread.

Summary

West Pharmaceutical Services (NYSE: WST) and Stevanato Group (NYSE: STVN) both printed Q2 FY2026 results that keep GLP-1 hardware as a disclosed, growing slice of sales — but the load-bearing mix numbers sit on decks and remarks, not on the press-release highlights. West raised FY26 sales and adj-EPS; the 18% GLP-1 mix is deck-only (10% elastomer + 8% West Vantage) and must not be read as all-elastomer tightness. Stevanato narrowed FY revenue, printed HVS +16%, and put GLP-1 at 22–23% of Q2 revenue on slides plus Franco remarks — not in the 6-K highlights. Official West transcript was not retrieved. Oral GLP-1 is a live derailer, not a printed mix collapse: Foundayo approved and shipping; Wegovy pill is expanding the class on brand tape; class-level oral share >30% is not established. 503B is closing, not reopening: FDA proposed (91 FR 23431) not to list semaglutide, tirzepatide, and liraglutide on the 503B Bulks List — a proposal, not a final designation; comment window later extended to 30 Jul (FR-2026-12937, fetched this pass). No final rule fetched. WST/STVN mix is up, not down. Injectable unit volumes still undisclosed. Last prices are the Thu 27 Aug 2026 4:00 PM EDT close. No buy/sell/size. No Gage range.

Findings

West — Q2 FY2026 company print (8-K 23 Jul 2026 + IR)

From the West Q2 2026 IR release and the Form 8-K dated 23 Jul 2026:

  • Sales $872.3M, +13.8% reported / +12.7% organic.
  • Diluted EPS $2.15; adjusted $2.37.
  • FY26 raised to $3.345–$3.380B sales / $8.85–$9.05 adj EPS. Prior on the same page: $3.295–$3.350B / $8.40–$8.75.
  • Segment organic: HVP Components $424.1M +18.4%; HVP Delivery Devices $131.2M +29.2%; West Vantage $149.7M +0.8%.
  • Green (IR): HVP Components on biologics, Annex 1, and ongoing growth in GLP-1 elastomers. The IR release names GLP-1 elastomers qualitatively only.

West — GLP-1 mix is deck-only

From the Q2 2026 earnings deck:

  • GLP-1 mix: 10% elastomer + 8% West Vantage = 18% of Q2 net sales.
  • Do not treat 18% as all-elastomer tightness. The elastomer leg is the 10% slice; West Vantage is the 8% slice and printed only +0.8% organic in the IR/8-K.
  • Official West transcript was not retrieved. Do not file Benzinga oral-cannibalization quotes unless a West-hosted or SEC transcript is fetched.

Stevanato — Q2 FY2026 company print (6-K EX-99.1 4 Aug)

From the SEC 6-K Exhibit 99.1 (mirrored on IR as stvn-ex99_1 0001193125-26-332769 path for slides and 0001193125-26-332815 for the IR transcript):

  • Revenue €302.0M +8%.
  • HVS €135.9M +16%, 45% of sales.
  • Diluted EPS €0.08; adjusted €0.14.
  • FY guide narrowed to €1.260–€1.280B. Balda sale €12.2M one-time; ~€30M FY revenue out.
  • Fishers: first EZ-fill vial PQ done; full ramp end-2028. Latina RTU 400 commercial 2027. Demand “strong and robust.”
  • NYSE: STVN confirmed.

Stevanato — GLP-1 mix and contested biologics split

  • GLP-1 22–23% of Q2 revenue is slides + Franco remarks, not in the 6-K press-release highlights. Leave that label on the number.
  • Contested: slides “Biologics that grew 30% yoy” vs Franco Q&A “6% of growth in biologics.” Leave the split. Do not flatten.

Last prices (Thu 27 Aug 2026 4:00 PM EDT)

Valuation block + empty Gage only. No invented range, target, downside, or horizon. Not a buy/sell/size.

Oral GLP-1 — live derailer, not a printed mix collapse

Orals are live. They are not printed as a WST/STVN mix collapse. Q2 hardware mix is up, not down. Injectable unit volumes remain undisclosed. Do not invent class-level oral share.

  • Lilly IR, 1 April 2026: FDA approved Foundayo (orforglipron), “the only GLP-1 pill”; shipping 6 April 2026.
  • Novo / PR Newswire Wegovy pill: Wegovy pill 3 million prescriptions since 5 January 2026; more than 80% of new Rx new-to-GLP-1 (expanding, not replacing). Injectable Wegovy HD also strong on that release.
  • Class-level oral share >30% is not established. Brand-mix tape (Foundayo launch; Wegovy pill 80% new-to-class) is not class share. Do not treat it as the falsifier tripwire.

503B — closing, not reopening

  • 91 FR 23431 (1 May 2026): FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. Original comment deadline June 30, 2026. This is a proposal, not a final designation.
  • Comment window later extended to 30 July 2026. Fetched this pass: FR Doc. 2026-12937 (26 June 2026) — Docket FDA-2018-N-3240; extends the May 1 notice (91 FR 23431); comments due July 30, 2026. The notice says comments “will inform FDA’s final determination.” No final rule was fetched. Do not invent a final.

What this pass did not fetch

Leave open. Do not invent.

  • Green orals expanding vs cannibalizing; +4 pts price; Dublin ramp (31 Mar IR) — only if a West-hosted or SEC primary is fetched.
  • STVN one-customer variable compensation for missed committed volumes — only if fetched on a Stevanato primary.
  • Q1 70/30 injectable/oral as a long-run opportunity, not current TRx — only if fetched.
  • Official WST transcript (West-hosted or SEC). Benzinga oral-cannibalization quotes stay out.
  • Bachem Building K ad-hoc; BANB / Ypsomed / Schott US-listed line. No Swiss entity pages from this clip.
  • LLY orexin / Centessa. Encyclopedia is not a source.

Contradictions and open questions

  • WST 18% GLP-1 mix is deck-only, split 10% elastomer / 8% West Vantage. IR names GLP-1 elastomers qualitatively. Do not treat 18% as elastomer tightness.
  • STVN 22–23% GLP-1 is slides + Franco, not 6-K highlights.
  • STVN biologics: slides 30% yoy vs Franco “6% of growth.” Leave split.
  • Official WST transcript not retrieved. West-hosted oral-cannibalization color stays open. Brand-level oral tape (Foundayo / Wegovy pill) is filed; class-level oral share >30% is not established.
  • 503B is still a proposal. 91 FR 23431 + comment extension to 30 Jul. No final rule fetched.
  • June honest gap stays open: whether WST/STVN face supply constraints sufficient to command pricing power, or whether capacity has normalized post-shortage, is still inferred. Q2 mix-up does not close it. Injectable unit volumes still undisclosed.
  • Scout extras above remain unfetched.

Provenance

Method: Grok Bot / Alfred-fetched issuer primaries / stockanalysis last prices / scout part 2 orals+503B folded here / FR-2026-12937 fetched this pass / native X not used this pass Generated: 2026-08-28

Web sources:

X sources:

  • none found this pass — grain was issuer/SEC/IR + stockanalysis only

Grokipedia:

  • not used
Referenced by
Mechanisms
GLP-1 demand surge → four-layer manufacturing bottleneck → Bachem / Stevanato / West Pharma / Ypsomed
Questions
Is the GLP-1 demand surge creating an injectable supply-chain bottleneck that benefits Bachem, Stevanato, and West Pharma?
Entities
Stevanato Group (NYSE: STVN)West Pharmaceutical Services (NYSE: WST)